Atrys Health SL Asset Resilience Ratio
Atrys Health SL asset resilience ratio. Atrys Health SL (ATRY) has an Asset Resilience Ratio of 0.08% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Atrys Health SL (ATRY) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Atrys Health SL (2012–2025)
Asset resilience ratio of Atrys Health SL from 2012 to 2025. This chart shows how Atrys Health SL's Asset Resilience Ratio has changed over time. Read ATRY total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Atrys Health SL's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ATRY total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €259.00K | 0.08% |
| Total Liquid Assets | €259.00K | 0.08% |
Asset Resilience Insights
- Limited Liquidity: Atrys Health SL maintains only 0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Atrys Health SL Industry Peers by Asset Resilience Ratio
Compare Atrys Health SL's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Atrys Health SL Asset Resilience Ratio by Year (2012–2025)
Atrys Health SL asset resilience ratio by year from 2012 to 2025. The table below shows the annual Asset Resilience Ratio data for Atrys Health SL.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.95% | €4.69 Million ≈ $5.48 Million |
€494.04 Million ≈ $577.59 Million |
-0.58pp |
| 2024-12-31 | 1.53% | €8.93 Million ≈ $10.43 Million |
€584.19 Million ≈ $682.98 Million |
+1.44pp |
| 2023-12-31 | 0.09% | €554.00K ≈ $647.68K |
€629.00 Million ≈ $735.37 Million |
-0.16pp |
| 2022-12-31 | 0.25% | €1.77 Million ≈ $2.07 Million |
€705.28 Million ≈ $824.55 Million |
-0.91pp |
| 2021-12-31 | 1.16% | €6.57 Million ≈ $7.68 Million |
€565.63 Million ≈ $661.28 Million |
-8.86pp |
| 2020-12-31 | 10.02% | €17.61 Million ≈ $20.59 Million |
€175.78 Million ≈ $205.50 Million |
+0.07pp |
| 2019-12-31 | 9.95% | €8.76 Million ≈ $10.24 Million |
€88.04 Million ≈ $102.93 Million |
-8.51pp |
| 2018-12-31 | 18.46% | €9.91 Million ≈ $11.59 Million |
€53.69 Million ≈ $62.77 Million |
+18.11pp |
| 2017-12-31 | 0.35% | €141.87K ≈ $165.86K |
€40.20 Million ≈ $46.99 Million |
-0.23pp |
| 2016-12-31 | 0.59% | €179.05K ≈ $209.33K |
€30.57 Million ≈ $35.74 Million |
+0.39pp |
| 2015-12-31 | 0.19% | €50.21K ≈ $58.70K |
€26.10 Million ≈ $30.51 Million |
-0.06pp |
| 2014-12-31 | 0.26% | €50.21K ≈ $58.70K |
€19.53 Million ≈ $22.83 Million |
-1.37pp |
| 2013-12-31 | 1.63% | €307.64K ≈ $359.67K |
€18.87 Million ≈ $22.06 Million |
-13.65pp |
| 2012-12-31 | 15.28% | €2.80 Million ≈ $3.27 Million |
€18.29 Million ≈ $21.39 Million |
-- |
About Atrys Health SL
Atrys Health, S.A., together with its subsidiaries, provides diagnostic services and medical treatments in Spain, Portugal, and Latin America. It operates through three segments: Diagnosis, Oncology, and Preventive Medicine. The company offers integrated diagnostics services comprising structural and molecular pathology, genetics, and nuclear medicine diagnosis; telediagnosis activities in the fi… Read more